ARS Pharmaceuticals Inc. announced that its product neffy® (epinephrine nasal spray) has been approved in China as the first and only community use epinephrine product for the treatment of allergic reactions (anaphylaxis). This approval allows adults and children over 30 kg living with severe allergic reactions to access epinephrine outside of hospital settings for the first time in China. Under an exclusive licensing agreement, Pediatrix Therapeutics holds the rights to commercialize neffy in China and plans to make the product available in the spring of 2026. ARS Pharma will receive a final regulatory milestone payment of $4 million and is eligible for up to $80 million in sales milestones, in addition to tiered royalties on annual net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9617755-en) on December 29, 2025, and is solely responsible for the information contained therein.